Table 3.

Competing Risk Regression Analysis for Freedom from Recurrence among Patients Who Received Trimodality Therapy

	FFR
Univariate	SHR†	95% CI	p
Age, years
≤60	Ref.
>60	0.39	0.19–1.73	0.2
Sex
Male	Ref.
Female	1.30	0.57–2.98	0.5
Masaoka-Koga Disease Stage
I–III	Ref.
IVa	5.37	2.23–12.92	<0.001
Histology
Thymoma	Ref.
Thymic carcinoma	1.54	0.51–4.62	0.4
Resection Status
R0	Ref.
R1	1.05	0.43–2.93	0.9
R2/Unresectable	1.40	0.20–9.81	0.7
ECOG Performance Status Score
0	Ref.
1	2.49	0.63–9.89	0.2
2–3	8.17	1.22–54.73	0.03
Diagnosis year
Continuous	1.07	0.99–1.15	0.08

Abbreviations: SHR, subhazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; SUV_max, maximum standardized uptake value

^†Subhazard ratio based on competing risk analysis.